The Global HIV Vaccine Enterprise organized a one and a half-day workshop that brought together key experts in the field to discuss the conduct of efficacy trials of potential new immune-based approaches to interrupt MTCT of HIV, such as vaccines or passive immunization with monoclonal antibodies. The workshop was a follow-up on the Enterprise-organized meeting held in 2013 in Entebbe, Uganda. The meeting assessed the state of the field, identified gaps responsible for the remaining infant infections, and fostered discussion of the various aspects of conducting efficacy trials in the affected populations, using as a case study the proposed trial of a long-lasting broadly neutralizing antibody VRC01-LS in the context of standard of care prevention practices. The meeting was by invitation only, but the outcomes of these discussions will be shared with the wider research community.
Date: February 6-7, 2017
Watch the webinar here!
Radisson Blu Hotel & Residence
A meeting report and a webinar to present the meeting outcomes to a larger audience.
Coleen Cunningham, Duke University
Barney Graham, Vaccine Research Center, NIH
Ilesh Jani, Instituto Nacional de Saúde, Mozambique
Philippa Musoke, Makerere University
Sallie Permar, Duke University
Gabriella Scarlatti, Global HIV Vaccine Enterprise
Yegor Voronin, Global HIV Vaccine Enterprise
If you have any questions about the meeting, please contact Yegor Voronin at firstname.lastname@example.org